WUHN - M2Bio Sciences & Juvenescence - 7. The Potential of the Medical Psychedelics
Sounds like a business relationship is in the works between M2Bio CEO Jeff Robinson, Greg Bailey and Jim Mellon in the Psychedelic field. This connection is massive!
From Biohaven to Juvenescence Although a doctor by training, Dr. Bailey has a long track record in the industry. Juvenescence is his fourth senior biotech company.
Others include Medivation, which was bought by Pfizer for USD 14 billion, and Biohaven, which trades on the New York Stock Exchange $BHVN) and currently has a market capitalisation of more than USD 4 billion.
Juvenescence has raised USD $250 million to-date to create joint ventures and build an ecosystem of seasoned drug developers to support scientists, universities, and institutions specializing in ageing, senescence, and the diseases of ageing.